TY - JOUR T1 - TP53、KRAS和EGFR突变在非小细胞肺癌中的预后价值:EUELC队列JF -欧洲呼吸杂志》乔和J SP - 177 LP - 184欧元——六世- 40是10.1183/09031936.00097311 - 1 AU Scoccianti Chiara AU - Vesin Aurelien盟,马特尔Ghislaine AU -奥利弗,Magali盟——Brambilla伊丽莎白AU - Timsit,让非盟- Tavecchio卢卡盟——Brambilla基督教非盟-字段,皮埃尔·约翰·k . AU -埃诺盟,Y1 - 2012/07/01 UR - //www.qdcxjkg.com/content/40/1/177.abstract N2 - Nonsmall细胞肺癌样本欧洲早期肺癌生物进行分析评估的预后意义TP53突变喀斯特和表皮生长因子受体基因。该系列包括11名从不吸烟的人，86名曾经吸烟的人，152名现在吸烟的人和1名未告知吸烟状况的病人。鳞状细胞癌(SCCs) 110例，腺癌(adc) 133例，大细胞癌或混合型7例。免疫组化分析p53的表达。从冷冻的肿瘤组织中提取DNA。48.8%的病例检测到TP53突变，在scc中比adc中更常见(p lt;0.0001)。TP53突变状态与预后无关。已知与吸烟有关的G - T转换在发生第二原发肺癌或复发/转移(进展性疾病)的患者中略微更为常见。 EGFR mutations were almost exclusively found in never-smoking females (p=0.0067). KRAS mutations were detected in 18.5% of cases, mainly ADC (p<0.0001), and showed a tendency toward association with progressive disease status. These results suggest that mutations are good markers of different aetiologies and histopathological forms of lung cancers but have little prognostic value, with the exception of KRAS mutation, which may have a prognostic value in ADC. ER -